RISEDRONATE (risedronate sodium)
OSTEOPOROSIS AGENTS · POSTMENOPAUSAL OSTEOPOROSIS
SUN PHARMACEUTI
Drug class
Osteoporosis Agents
Osteoporosis agents comprise a broad therapeutic category of medications used to prevent bone loss, increase bone mineral density, and reduce fracture risk. Read more about Osteoporosis Agents
114 drugs in this class 61 manufacturers
Drugs in Osteoporosis Agents
EVENITY (romosozumab-aqqg)
OSTEOPOROSIS AGENTS · OSTEOPOROSIS IN POSTMENOPAUSAL WOMAN AT HIGH RISK FOR FRACTURE
AMGEN
BINOSTO (alendronate sodium)
OSTEOPOROSIS AGENTS · POSTMENOPAUSAL OSTEOPOROSIS ·+1
ASCEND THERAPEU
FOSAMAX (alendronate sodium)
OSTEOPOROSIS AGENTS · POSTMENOPAUSAL OSTEOPOROSIS ·+1
ORGANON LLC
MIACALCIN (calcitonin,salmon,synthetic)
HYPERCALCEMIA AGENTS · HYPERCALCEMIA TREATMENT ADJUNCT ·+2
MYLAN INST-NOVA
MIACALCIN (calcitonin,salmon,synthetic)
HYPERCALCEMIA AGENTS · HYPERCALCEMIA TREATMENT ADJUNCT ·+2
MYLAN INSTITUTI
FOSAMAX PLUS D (alendronate sodium/cholecalciferol (vitamin D3))
OSTEOPOROSIS AGENTS · POSTMENOPAUSAL OSTEOPOROSIS ·+1
ORGANON LLC
RECLAST (zoledronic acid in mannitol and water for injection)
HYPERCALCEMIA AGENTS · PAGET'S DISEASE OF BONE ·+5
Novartis Pharmaceuticals
BINOSTO (alendronate sodium)
OSTEOPOROSIS AGENTS · POSTMENOPAUSAL OSTEOPOROSIS ·+1
RADIUS HEALTH,
Filter & compare in the drug finder →
Opens the drug finder with Osteoporosis Agents preselected. Add indication or manufacturer filters there.
Osteoporosis agents comprise a broad therapeutic category of medications used to prevent bone loss, increase bone mineral density, and reduce fracture risk.
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation.
Clinically, these agents are primarily indicated for the management and prevention of postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced bone loss.
-
fda.gov
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation
-
nih.gov
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation
-
nih.gov
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation
-
nih.gov
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation
-
nih.gov
The class includes antiresorptive medications—such as bisphosphonates, RANK ligand inhibitors, and selective estrogen receptor modulators—which suppress osteoclast-mediated bone breakdown, as well as anabolic therapies like parathyroid hormone receptor agonists and sclerostin inhibitors that stimulate osteoblastic bone formation
-
nih.gov
Clinically, these agents are primarily indicated for the management and prevention of postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced bone loss
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.